The Center for Technology Licensing (CTL) is Cornell University's technology transfer office.
We manage technology for Cornell's Ithaca campus, Weill Cornell Medical Colleges, Cornell Tech and the New York State Agricultural Experiment Station in Geneva.
3D Bio Therapeutics is a bioprinting platform company focused on whole tissue living implants for near term indications, which fully integrate into body and become nearly indistinguishable from native tissue.
Acuamark Diagnostics is developing novel diagnostic tests to enable low-cost and accurate early detection of colorectal cancer directly from the blood, by isolating and identifying multiple cancer markers. Thus, allowing for improved sensitivity, specificity, and scalability.
AffyImmune is an immuno-oncology company that develops T cell products for cancer therapy. The company was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors. The company has two products in the pipeline, and are ready to commence clinical trials in 2018
Akelos Inc. is a biopharmaceutical clinical company developing novel non-opioid, anti-hyperalgesic drugs for the treatment of neuropathic pain. Their compounds are intended to selectively and potently inhibit HCN1 channel activity to limit pain.
Androvia LifeSciences is a NY-based, privately held company focused on developing new diagnostics that provide a higher level of patient management of male fertility for use by clinicians to counsel couples. The company’s objective is to understand male fertility at its most fundamental level – how it occurs, how it’s measured, and how it can be applied to improve outcomes.
ANSwers Neuroscience, Inc. (formerly B2D2, Inc.) is committed to a vision of objective and standardized testing for patients who suffer from post-concussive symptoms, as well as potential solutions for the road to recovery.
ArcScan, Inc., is developing Artemis 3, a high-resolution ultrasound scanner that enables eye surgeons to design phakic and accommodative lenses to reduce the risk of bad outcomes in corneal surgeries and lens implants.
Bactana Animal Health is a global development stage animal health company. Its product development platform (FPS-4) is initially being developed for food animals and has demonstrated increases in yield efficiency, weight gain, and improved gut health through enhancement to an animal’s microbiome.
Big Blue Biotech produces a novel catheter system designed to decrease the risk of contamination of urine specimens with peri-urethral bacteria when obtaining urine specimens from pediatric patients via bladder catheter.
Bionic Sight develops neuro-prosthetics—prosthetic devices to treat blindness due to retinal degenerative disease that interact with the nervous system in order to restore function to damaged or degenerated tissue in the eye. The company is developing a technique involving gene therapy and a wearable device that correctly transmits light pulses to the brain, giving the wearer sight.
Biosleep uses a proprietary algorithm and cloud-based analytics to conveniently and accurately diagnose sleep apnea. The economic impact of undiagnosed sleep apnea is roughly $150B per annum. Less than 20% of patients suffering with obstructive sleep apnea have been currently diagnosed.
BlinkBio, Inc. employs specialized Bioorthogonal chemistries for the delivery of next generation medicines for the treatment of cancer and other diseases. BlinkBio has optimized their proprietary chemistries into two types of novel linkers: one that allows the improved targeting of cytotoxic cancer medicines designed to rapidly kill cancer cells (so called Small Molecule Drug Conjugates (SMDCs) and Antibody Drug Conjugates (ADCs)); and the other that designs larger self-assembling therapeutics to target important cancer genes (such as MYC and p53) which exist inside cells and are not addressable using more traditional cancer therapeutics.
bloXroute is a blockchain scalability solution that allows all cryptocurrencies and blockchains to scale to thousands of transactions per second (TPS) on-chain, without any protocol changes. bloXroute solves the scalability bottleneck by addressing the substantial time required for all nodes to synchronize when handling large volumes of TPS. Most importantly, bloXroute does this in a provably neutral way.
Bodi Energy is focused on the next generation of lithium-ion batteries. By incorporating a novel electrospray process to create a scalable film and adding a 2-D sheet of conductive graphene, Bodi Energy is advancing the use of silicon-based materials for efficient energy storage in batteries.
C2i Genomics helps doctors and patients fight cancer by providing doctors and patients with tumor burden information, starting with only a blood sample. Its service, called C2, uses software that performs pattern recognition on data from whole genome sequencing of the blood sample. Physicians can use the service to monitor their patient’s response to treatment, and detect treatment failure or disease recurrence well before they would do otherwise. It can also be used to measure treatment response in clinical trials.
Cleerly is devoted to generating predictive and diagnostic software products using machine learning on radiological image data. The machine learning strategy licensed from Cornell can make connections and inferences about health that a human brain would miss. Their first round of products will be aimed at assessing heart health and will provide a user friendly platform for doctors and patients to learn about their heart by exploiting the connections made using the machine learning strategy. The technology was developed in the Dalio Institute for Cardiovascular Imaging.
Computational Textiles, Inc is a small employee-owned company founded to create textile visualization and manufacturing software. The company’s first product, Weft, is a web application and manufacturing process that enables anyone to transform design ideas into intricately patterned woven cloth.
Conamix is commercializing high performance battery materials based on proprietary Cornell technology. The company’s unique battery materials allow higher energy density in existing lithium ion architectures and are manufactured using low cost and highly commercial methods.
CycloPure is engaged in the design, development and commercialization of a new class of highly-adsorbent materials for use in the separation and removal of pollutants, VOCs and other organic compounds from water and air.
Through effective utilization of light energy, Dimensional Energy’s HI-Light Reactor makes it possible to lower the pressures and temperatures necessary for energy-intensive chemical reactions to occur. This makes it possible to convert molecules such as carbon dioxide into feedstocks for downstream chemical and fuel processes. Dimensional Energy’s creative business model and artificial photosynthesis process aim to actively address the problem of climate change by providing profitable pathways to utilize renewable energy in carbon-intensive industries.
Dryfiber, LLC is a subsidiary of DryWired that is developing stain resistant coatings for surfaces and textiles using fluorine-free polymer chemistry. The coating process disburses a thin polymeric coating on a surface, imparting a microscopically rough texture that can resist staining from vegetable, olive, and other oils. When applied textiles, there is no noticeable impact on the feel or softness of the fabric.
Ecolectro develops structurally robust and highly conductive polymer membranes for a range of applications, including electrolysis and fuel cell systems that not only improve performance but also dramatically decrease costs.
Embark is a veterinary science-focused company specializing in canine genetics. Through the use of cutting-edge genetic testing and analysis, Embark offers 21st century pet wellness advice coupled with comprehensive ancestry, morphological trait, and genetic disease information for dog owners.
Fesarius Therapeutics is developing engineered tissue scaffold products for the skin and dermal layers. The products are based off the patent-pending microstructure-containing gel scaffold technology developed at Cornell. The acellular skin replacement will aim to benefit those with wounds resulting from burns, plastic surgery, tumor removal, and other forms of trauma.
Fitzroy Salute, LLC offers an affordable and comprehensive environmental health and safety information management solution to streamline and improve EHS operations. The cloud-based IMS provides environmental health and safety staff with integrated modules for hazard assessment, safety and compliance, metric tracking, and more. Fitzroy Salute, LLC provides academic and healthcare institutions the tools they need to foster a true culture of safety, rather than just compliance.
GNS Healthcare applies its groundbreaking, powerful artificial intelligence (AI) platform to unravel the complexity of human disease in order to match the right treatment to the right patient at the right time.
Guard Medical, a privately-held company, is developing easy-to-use and cost-effective solutions that enable prophylactic Negative Pressure Wound Therapy (NPWT) wound care of closed surgical incisions. Guard Medical’s simple NPWT technology originated with New York – Presbyterian and Weill Cornell Medicine in response to physicians’ identification of unmet needs related to Surgical Site Infections (SSI). Its investors include Bpifrance and Matignon Investissement et Gestion. Guard Medical’s vision is to develop NPWT solutions for use on a wide range of surgical wound types and sizes with broad applications for infection prevention, scar mitigation and enhanced cosmesis.
HµREL Corporation develops bioanalytic devices that are used in pharmaceutical development and industrial and consumer product safety testing. A HµREL® is a microfluidic circuit that models real-time protein binding, metabolism, and extraction in the liver.
Halomine develops rechargeable antimicrobial technologies for uses in healthcare facilities, food processing plants, etc. The lead product, HaloFilm, is a unique rechargeable antimicrobial liquid spray that creates an antimicrobial film on almost any surface. HaloFilm offers a continuous protection against microbes on surface materials such as on stainless steel, plastics, coat of paint, or rubber.
Hemogenyx Therapeutics is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (â€œBMâ€) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells.
Immunovent, LLC is focused on the commercialization of next-generation technologies for allergy diagnosis. The company is developing the Local Allergy Mucosal Brush Test (LAMB-Dx), the first quantitative allergy diagnostic that will enable physicians to accurately test for both airborne and food allergies precisely where the clinical symptoms are occurring – in the mouth and nose.
Lucerna, Inc., is a biotechnology research company focused on developing and commercializing nucleic-acid based fluorescent sensors for Point-of-Care therapeutic diagnostics and environmental biomonitoring. Lucerna also offers newly developed antibodies for proteomic research.
Lumendi Ltd., is focused on the development of new minimal invasive surgical tools and devices that will provide solutions for minimally invasive gastrointestinal surgeries. The company’s first product is an add-on to any commercially available endoscope that will avoid invasive colon resections to treat more complex gastrointestinal diseases.
Metro Mid-Atlantic Biotech is a development stage startup focused on developing novel small molecule therapeutics based on discoveries in the molecular mechanisms of aging and longevity in mammalian cells.
MiTeGen, LLC, designs and manufactures products for X-ray diffraction and crystallography of proteins and small molecule/inorganic compounds, and for manipulation and measurement of small samples in cell biology, histology, clinical diagnostics, entomology, archaeology, and geology.
NOHMs Technologies, Inc., is a battery materials manufacturer (anode, cathode, and electrolyte) with a vision to improve and commercialize promising new nanoscale chemistry for better battery technology.
Noria is a radiotherapy company developing targeted therapeutic and imaging radiopharmaceuticals (alpha-emitting) for use in oncology. The lead oncology therapeutic candidate is PSMA-PK-Rx. This product will be used for the treatment of metastatic castrate resistant prostate cancers (mCRPC). This therapeutic can be ‘paired’ with their PSMA imaging agent PSMA-PK-Dx to create a unique theranostic alternative for men suffering with prostate cancer. The company’s pipeline includes SOMA-PK-Rx and SOMA-PK-Dx another theranostic pairing for the treatment and imaging of neuroendocrine cancers, respectively.
Novita Pharmaceuticals, Inc. is a biopharmaceutical startup developing target-specific small molecule drugs to treat cancer metastasis. The company is currently focusing on patients with metastatic breast cancer.
NYAG (New York Apple Growers), LLC, was formed around an exclusive license agreement for two new apple varieties, ‘New York 1’ and ‘New York 2’. This member owned company is open to all New York growers to help promote agricultural market growth within New York state.
OneThree Biotech is a VC backed startup developing a biology-driven Artificial Intelligence Technology Platform to accelerate drug discovery and development. The company’s platform enables the healthcare and pharmaceutical industry to quickly and accurately generate new testable insights and hypotheses by combing the world of systems and disease biology with computational tools to discover new treatments for patients in need. The platform helps identify novel targets, compounds and new drug combinations, as well as optimizes compounds for toxicity or efficacy.
Orthogonal, Inc., is developing environmentally safe, high-performance fluorinated photoresists to make “organic,” or carbon-based electronics on the same machinery manufacturers use to make silicon-based electronics.
Pacific Biosciences of California, Inc., is developing Single Molecule Real Time (SMRT™), a technology platform to detect biological events at single molecule resolution. Its first commercial application will be fast, low-cost DNA sequencing; future planned applications for the SMRT™ platform include RNA sequencing and analysis of protein synthesis.
Prendismo, LLC, is home to the world’s premiere collection of digital video content on business, leadership, and entrepreneurship. Prendismo arose from the eClips project at Cornell University and the Cornell Center for Technology Enterprise (CCTEC).
ReconnectNEURO is focused on the treatment of cognitive impairment through the use of deep brain stimulation methods. The stimulation systems work to increase consciousness in patients who are minimally conscious or who have reduced capacity due to trauma, stroke, or other diseases.
SafetyStratus, Inc., is a cloud computing company that distributes software on a subscription basis to research institutions. The company’s application, LabcliQ, is used for workflow and laboratory inspections.
Sonder Medicine uses extracellular vesicles from the vitreous humor as a potent vector to efficiently deliver recombinant proteins into the sensory tissue of the eye, the retina. Their proprietary technology can transport various payloads, including therapeutic proteins, nucleic acids and antibodies into the tissues of the human eye.
Aufbau Medical Innovations Ltd., wholly owns Sonder Medicine Inc., doing business as Sonder Research X in the United States.
Stealth BioTherapeutics, Inc., is a clinical stage, biopharmaceutical company developing novel mitochondrial targeted therapies for diseases with clear unmet medical needs including cardiovascular, renal and metabolic diseases. The company’s first clinical candidate, Bendaviaâ„¢, targets the mitochondria to treat cardio-renal and microvascular impairments.
Swiftscale Biologics provides fast production services for biologics. At any scale from micrograms to grams, Swiftscale can produce proteins. Swiftscale can produce antibodies, enzymes, receptors, and other complex protein forms. Swiftscale was co-founded by Matthew DeLisa, a professor at Cornell, and Michael Jewett, a professor at Northwestern.
Tetragenetics, Inc. (managed by University of Georgia Research Foundation, Inc.), is an early stage biotechnology company developing an alternative technology platform for the production of genetically engineered proteins for the treatment and prevention of human and animal disease.
The Mode Group operates the world’s highest-performing cloud private network. Mode Core offers MPLS reliability and QoS in a cloud service with a business-internet price point. Formerly known as Waltz Networks, Inc.
Tico Biosciences is developing a cell sample preparation platform designed to perform cellular sample processing. The company’s platform separates and isolates cellular components, enabling users to perform long-read DNA sequencing and multi-omic analysis.
Trace Imaging Technologies uses a cell labeling technique for use in PET and fluorescence imaging for quick, accurate and non-invasive imaging for emergency health complications such as intra-cerebral hemorrhages, brain injuries, intestinal bleeding etc.
Ukko Agro is building a smart agriculture ecosystem that uses prescriptive disease/pest management models and integrates with external on-farm machinery and equipment via IoT to help farmers optimize crop inputs to achieve higher yields. Ukko Agro ecosystem aims to offer a solution to critical questions about improving yields sustainably and cost-effectively for farmers, meeting sustainability standards for CPGs and in the end benefit consumers.
Uni actualizes inclusion by radically transforming how companies make smart decisions.
From figuring out quarterly objectives to planning weekly sprints, or just figuring out how to deal with a pesky bug, Uni let’s mannagers ask their teams impactful questions, stay true to their timelines, and have a set of ideas for when it is time to decide what to do.
Vernx Biotechnology is developing a range of nutrition products using branched fatty acids (BCFA) for multiple uses: to improve gastrointestinal health in pre-mature and non-premature infants, as a nutritional supplement for adults, and for eventual therapeutic use.
Versatope Therapeutics is using exosomes (extracellular vesicles) derived from genetically engineered probiotics as a technology platform for the targeted delivery of large molecules used in vaccines, therapeutics and diagnostics.
VitaMe Technologies (DBA VitaScan™) has developed a smartphone based diagnostic platform enabling accurate, fast, convenient, and low cost testing of vitamins and micronutrients in the home and at local pharmacies and clinics.
Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers. The company focuses on developing therapies for metastatic cancers by targeting key pathways related to chromosomal instability, a hallmark of cancer metastasis. The majority of oncology therapeutics target alterations widely found in primary tumors while metastasis is responsible for approximately 90% of cancer deaths. Volastra hopes to change the treatment paradigm for patients by developing novel therapeutics specifically tailored to advanced disease.
WOTN is a risk software company that provides an independent, real-time, simulation-based risk management platform for the $1T commercial mortgage backed securities market. The patent pending technology provides risk measurements on demand for loans and bonds in the derivative structure compliant with Basel in a comprehensive portfolio management system.
Xallent is developing the next generation of Scanning Probe Microscopes (SPM) to enable advanced, rapid, in-line testing of semiconductor devices and thin-films at the micro- and nano-scales. Patented technologies are based on integrating one or multiple tips with supporting sensing, actuation and electronics on a single probe chip. These “probe platforms-on-a-chip” are designed and fabricated using advanced nanoelectromechanical system (NEMS) technologies, enabling simple and cost-effective miniaturization to the nanoscale.
XyloCor is a clinical-stage biotechnology company dedicated to developing first-in-class gene therapies for patients with cardiovascular disease. The company’s lead product comprises the use of vascular endothelial growth factor for the treatment of diffuse coronary artery disease.
ZYMtronix is a biotechnology startup that services enzyme and pharmaceutical manufacturers. ZYMtronix immobilizes and optimizes biocatalysts for continuous manufacturing using green chemistry principles to lower the costs and increase the yields of drug manufacturing.